Active substance
Perindopril erbumine
- US FDA 6
- Health Canada 54
- US price lines 3
- NHS prices 3
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PERINDOPRIL ERBUMINE | 2MG; 4MG; 8MG | tablet · oral | AUROBINDO PHARMA | Prescription | 10 Nov 2009 |
| ACEON | 2MG; 4MG; 8MG | tablet · oral | SYMPLMED PHARMS LLC | Discontinued | 30 Dec 1993 |
| PERINDOPRIL ERBUMINE | 2MG; 4MG; 8MG | tablet · oral | ANI PHARMS | Discontinued | 10 Nov 2009 |
| PERINDOPRIL ERBUMINE | 2MG; 4MG; 8MG | tablet · oral | HIKMA PHARMS | Discontinued | 10 Nov 2009 |
| PERINDOPRIL ERBUMINE | 2MG; 4MG; 8MG | tablet · oral | LUPIN LTD | Discontinued | 27 Jan 2010 |
| PERINDOPRIL ERBUMINE | 2MG; 4MG; 8MG | tablet · oral | APOTEX | Discontinued | 30 Aug 2010 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-PERINDOPRIL ERBUMINE | 02529491 | 2 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-PERINDOPRIL ERBUMINE | 02529505 | 4 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-PERINDOPRIL ERBUMINE | 02529513 | 8 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-PERINDOPRIL | 02289261 | 2 MG | TABLET · ORAL | APOTEX INC |
| APO-PERINDOPRIL | 02289288 | 4 MG | TABLET · ORAL | APOTEX INC |
| APO-PERINDOPRIL | 02289296 | 8 MG | TABLET · ORAL | APOTEX INC |
| AURO-PERINDOPRIL | 02459817 | 2 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-PERINDOPRIL | 02459825 | 4 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-PERINDOPRIL | 02459833 | 8 MG | TABLET · ORAL | AURO PHARMA INC |
| BIO-PERINDOPRIL | 02501309 | 2 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-PERINDOPRIL | 02501317 | 4 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-PERINDOPRIL | 02501325 | 8 MG | TABLET · ORAL | BIOMED PHARMA |
| COVERSYL | 02123274 | 2 MG | TABLET · ORAL | SERVIER CANADA INC |
| COVERSYL | 02123282 | 4 MG | TABLET · ORAL | SERVIER CANADA INC |
| COVERSYL | 02246624 | 8 MG | TABLET · ORAL | SERVIER CANADA INC |
| JAMP PERINDOPRIL ERBUMINE | 02527200 | 2 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP PERINDOPRIL ERBUMINE | 02527219 | 4 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP PERINDOPRIL ERBUMINE | 02527227 | 8 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-PERINDOPRIL ERBUMINE | 02482924 | 2 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-PERINDOPRIL ERBUMINE | 02482932 | 4 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-PERINDOPRIL ERBUMINE | 02482940 | 8 MG | TABLET · ORAL | MANTRA PHARMA INC |
| MAR-PERINDOPRIL | 02474824 | 2 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-PERINDOPRIL | 02474832 | 4 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-PERINDOPRIL | 02474840 | 8 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MINT-PERINDOPRIL | 02476762 | 2 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
29 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PERINDOPRIL ERBUMINE 2 MG TAB | $0.48838 | per EA | 23 Sep 2026 |
| US NADAC | PERINDOPRIL ERBUMINE 4 MG TAB | $0.49469 | per EA | 23 Sep 2026 |
| US NADAC | PERINDOPRIL ERBUMINE 8 MG TAB | $0.54204 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Perindopril erbumine 2mg tablets | £1.22 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Perindopril erbumine 4mg tablets | £1.58 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Perindopril erbumine 8mg tablets | £3.47 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Sep 2017 ACEON — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.